Recce Pharmaceuticals (ASX:RCE) EPS without NRI: A$-0.11 (TTM As of Dec. 2025)


ASX:RCE Recce Pharmaceuticals Ltd ASX:RCE
31 GF Score
Price A$0.38
! 4 Warning Signs
View Full Analysis

What is Recce Pharmaceuticals EPS without NRI?

Recce Pharmaceuticals ASX:RCE -6.17% 31 EPS without NRI is A$-0.11 as of Dec. 2025. GuruFocus rates ASX:RCE with a GF Score™ of 31/100. The stock has 4 warning signs investors should review. Among 1,171 Biotechnology companies, Recce Pharmaceuticals ranks worse than 82.84% on this metric.

Recce Pharmaceuticals's earnings per share without non-recurring items for the six months ended in Dec. 2025 was A$-0.06. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.11.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Recce Pharmaceuticals's EPS without NRI or its related term are showing as below:

ASX:RCE' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -64.8   Med: -13.2   Max: 30.1
Current: -13.2

ASX:RCE's 3-Year EPS without NRI Growth Rate is ranked worse than
82.84% of 1171 companies
in the Biotechnology industry
Industry Median: 16.8 vs ASX:RCE: -13.20

Recce Pharmaceuticals's EPS (Diluted) for the six months ended in Dec. 2025 was A$-0.06. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.11.

Recce Pharmaceuticals's EPS (Basic) for the six months ended in Dec. 2025 was A$-0.06. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.11.


Recce Pharmaceuticals  (ASX:RCE) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Recce Pharmaceuticals EPS without NRI Related Terms


Recce Pharmaceuticals EPS without NRI Historical Data

* Premium members only.

The historical data trend for Recce Pharmaceuticals's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Recce Pharmaceuticals EPS without NRI Chart

Recce Pharmaceuticals Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.09 -0.06 -0.07 -0.10 -0.09

Recce Pharmaceuticals Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.04 -0.06 -0.03 -0.06 -0.06

ASX:RCE vs VRTX, REGN, ALNY: EPS without NRI Comparison

For the Biotechnology subindustry, Recce Pharmaceuticals's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Recce Pharmaceuticals PE Ratio without NRI vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Recce Pharmaceuticals's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Recce Pharmaceuticals's PE Ratio without NRI falls into.


ASX:RCE
31GF Score
Recce Pharmaceuticals Ltd ASX:RCE
EPS without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Recce Pharmaceuticals EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-0.11

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS without NRI →
What does a EPS without NRI of A$-0.11 mean?
Recce Pharmaceuticals (ASX:RCE) has a EPS without NRI of A$-0.11 as of Dec. 2025. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Recce Pharmaceuticals and its competitors. According to the industry distribution chart, Recce Pharmaceuticals ranks #970 out of 1171 companies in the Biotechnology industry, placing it in the top 82.8%.
Is Recce Pharmaceuticals' EPS without NRI too high?
Recce Pharmaceuticals' current EPS without NRI is A$-0.11. Based on the distribution chart, Recce Pharmaceuticals ranks #970 out of 1171 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Recce Pharmaceuticals has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Recce Pharmaceuticals' EPS without NRI compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Recce Pharmaceuticals ranks #970 out of 1171 companies for EPS without NRI. This places Recce Pharmaceuticals in the lower half of its industry. The industry median EPS without NRI is 16.80. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Biotechnology company?
The median EPS without NRI among Biotechnology companies is 16.80, based on 1,171 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Recce Pharmaceuticals and its competitors. For the Biotechnology industry, the median EPS without NRI is 16.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Recce Pharmaceuticals's current EPS without NRI is A$-0.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Recce Pharmaceuticals stock overvalued right now?
Recce Pharmaceuticals (ASX:RCE) has a current EPS without NRI of A$-0.11. The current EPS without NRI is A$-0.11. Recce Pharmaceuticals' overall GF Score™ is 31/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Recce Pharmaceuticals (ASX:RCE), the current EPS without NRI is A$-0.11 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Recce Pharmaceuticals Business Description

Other Exchanges R9Q:Germany
Address 3 Brodie Hall Drive, Suite 10, Technology Park, Bentley, WA, AUS, 6102
Recce Pharmaceuticals Ltd is an Australia-based, globally-focused biotechnology company that is pioneering the development and commercialisation of a drug discovery and development business commercialising new Classes of synthetic anti-infectives with broad-spectrum activity designed to address the urgent health threat of antibiotic-resistant superbugs and emerging viral pathogens. Its patented candidate, RECCE 327, has been developed for the treatment of life-threatening bacterial infections. It has one segment, which is the research and development of pharmaceutical drugs. Geographic segments are Australia, the UK, and the USA, of which the majority of the revenue comes from Australia. It offers antibiotic drugs to treat bacterial infections for Sepsis, Escherichia coli, and Others.
31GF Score

Get the complete analysis for ASX:RCE

EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.38
Price